GlucoTrack Inc (GCTK)

GlucoTrack, Inc. has experienced several significant events impacting its stock in the past six months. In Q3 2025, the company began a one-year, multicenter long-term feasibility study of its fully implantable CBGM system in Australia, following the successful completion of a first-in-human short-term clinical study in early 2025. The company secured $16.3 million in funding between late 2024 and early 2025, and further strengthened its balance sheet in Q3 2025 by securing $3.0 million via a Note Purchase Agreement and establishing a $20.0 million equity line of credit. GlucoTrack also reported its full-year 2024 financial results and announced the issuance of three new patents in January 2026. The company expects Investigational Device Exemption (IDE) approval for its CBGM technology from the FDA in Q4 2025.

Information regarding demand seasonality for GlucoTrack, Inc.'s products and services was not found in the provided search results. Demand would likely be driven by regulatory approvals, clinical adoption, and healthcare provider recommendations rather than seasonal consumer trends.

GlucoTrack, Inc. is a medical technology company focused on developing and commercializing innovative technologies for individuals with diabetes. Their primary focus is a long-term, implantable continuous blood glucose monitoring (CBGM) system designed to measure blood glucose levels directly from the blood, eliminating the lag time associated with traditional CGMs. The CBGM features a three-year sensor longevity, no on-body wearable component, and minimal calibration requirements. Previously, GlucoTrack developed the GlucoTrack® Model DF-F, a non-invasive glucose monitoring device, but has since shifted focus to its implantable solution.

GlucoTrack, Inc. has strategically shifted its focus to target the U.S. healthcare market by relocating to Mount Laurel, New Jersey in 2017. The company is expanding its clinical development internationally, initiating a one-year, multicenter long-term feasibility study of its fully implantable CBGM system in Australia in Q3 2025. The company's headquarters are in Rutherford, New Jersey, and it was originally founded in Israel.

GlucoTrack's brand reputation appears to be positively influenced by its advancements in clinical development and intellectual property. The successful completion of its first-in-human clinical study and the initiation of a long-term feasibility study in Australia are significant positive events. The granting of three new patents in January 2026 enhances its reputation as an innovator. The company's participation in the FORGETDIABETES European research initiative also contributes positively to its scientific standing.

Information regarding major institutional and individual owners of GlucoTrack, Inc. (GCTK) was not found in the provided search results.